Litcius/Paper detail

Defining NASH from a Multi-Omics Systems Biology Perspective

Lili Niu, Karolina Sulek, Catherine G. Vasilopoulou, Alberto Santos, Nicolai J. Wewer Albrechtsen, Simon Rasmussen, Florian Meier, Matthias Mann

2021Journal of Clinical Medicine23 citationsDOIOpen Access PDF

Abstract

Non-alcoholic steatohepatitis (NASH) is a chronic liver disease affecting up to 6.5% of the general population. There is no simple definition of NASH, and the molecular mechanism underlying disease pathogenesis remains elusive. Studies applying single omics technologies have enabled a better understanding of the molecular profiles associated with steatosis and hepatic inflammation-the commonly accepted histologic features for diagnosing NASH, as well as the discovery of novel candidate biomarkers. Multi-omics analysis holds great potential to uncover new insights into disease mechanism through integrating multiple layers of molecular information. Despite the technical and computational challenges associated with such efforts, a few pioneering studies have successfully applied multi-omics technologies to investigate NASH. Here, we review the most recent technological developments in mass spectrometry (MS)-based proteomics, metabolomics, and lipidomics. We summarize multi-omics studies and emerging omics biomarkers in NASH and highlight the biological insights gained through these integrated analyses.

Topics & Concepts

OmicsProteomicsSteatohepatitisMetabolomicsComputational biologyLipidomicsDiseaseMechanism (biology)MedicineBioinformaticsSystems biologyData scienceFatty liverComputer scienceBiologyPathologyGeneticsGeneEpistemologyPhilosophyLiver Disease Diagnosis and TreatmentMetabolomics and Mass Spectrometry StudiesLipid metabolism and biosynthesis